Dr. Spiros Servos is an RNA therapeutics expert and dealmaker with over 20 years of experience in the biotech industry. He holds a PhD in molecular biology, with a focus on constructing oral vaccines, and an MBA from Imperial College, demonstrating his deep understanding of both scientific principles and business strategy. Dr. Servos has a proven track record of success in commercializing cutting-edge gene therapy, vaccine and RNA therapeutics assets. His expertise lies in identifying and evaluating emerging technologies, building strong relationships with key stakeholders, and driving innovation in the RNA therapeutics space. Throughout his career, Dr. Servos has held key positions at Oxford Gene Technology, Emergent BioSolutions, Oxford BioMedica, and SiSaf, contributing significantly to the growth of the RNA therapeutics industry.
Dr Servos has a proven track record of securing over $110M in upfront payments through 30+ partnerships, totalling over $7B in value. Leveraging 20+ years of experience in gene therapy, he specializes in commercializing cutting-edge RNA therapeutics to improve patient access and affordability, particularly in neurodegenerative diseases. With a Ph.D. in molecular biology and an MBA from Imperial College, he possesses a deep understanding of both scientific principles and business strategy.
His key competencies include partnering, asset disposition, due diligence, technology scouting, alliance management, business intelligence, valuations, and revenue forecasting. He has a proven ability to identify and evaluate emerging technologies, build strong relationships with key stakeholders, and drive innovation in the RNA therapeutics space. By combining his scientific expertise with his business acumen, he has consistently delivered exceptional results for clients and contributed to the growth of the RNA therapeutics industry.
Key Competencies:
- Partnering
- Disposition of Assets
- Due Diligence
- Scouting for New Technologies
- Alliance Management
- Business Intelligence
- Valuations (Risk adjusted NPVs)
- Commercialisation Evaluation Algorith
